Using data from registries across Europe and Canada, Aymon et al. compared the incidence of major adverse cardiac events (MACE) in patients with RA treated with JAK inhibitors, TNF inhibitors or biologic DMARDs with other modes of action over two years. The researchers did not find an increased risk of MACE with JAK inhibitors over that time frame.
A EULAR 2025 review of Sjögren’s disease covered new pathogenic insights & promising phase 2 data for BTK inhibitors & CD40 pathway drugs.
With no FDA-approved drugs for Sjögren’s disease, experts share strategies for managing fatigue, arthritis, dryness, and systemic issues.
Over 50% of patients with systemic sclerosis (SSc) develop interstitial lung disease (ILD), and rheumatologists have long recognized this major cause of morbidity and mortality.1 Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, and director of the Toronto ScleroÂderma Program, notes that more recent studies have increased our awareness…
As the program enters its third round of negotiations, ACR members should be aware of several upcoming changes relevant to rheumatology.
This report presents a rare case of bilateral pulmonary artery stenosis secondary to granulomatosis with polyangiitis, underscoring the importance of recognizing large-vessel involvement as a potential manifestation of AAV; it also includes a narrative review analyzing eight previously reported cases.
A recent A&R review explores innovative, emerging therapies for the currently incurable, antibody-mediated disease antiphospholipid syndrome.
Summaries of selected research abstracts on the assessment & management of systemic vasculitis from ACR Convergence 2024.
An overview of highlights from the 2025 ECIM meeting, including research on treatment options for systemic sclerosis, the management of PMR & autoimmune testing.